Advanced non-small cell lung cancer in elderly patients: A review

Table 3 Phase II trials of cisplatin-based chemotherapy with third-generation agents and modified schedules or attenuated doses of cisplatin

Ref.	Regimen	CDDP dose	Age (yr)	No.of patients	RR	MST (mo)
1Mattioli et al[39]	CDDP + VNR	25 mg/m2, weekly	> 65	36	36%	11
Pereira et al[40]	CDDP + VNR	60-90 mg/m²	> 70	44	50%	7.5
Buffoni et al[41]	CDDP + VNR	30 mg/m², day 1 and 8	≥ 70	30	33%	7.4
Lippe et al[35]	CDDP + GEM	35 mg/m2, weekly	≥ 65	29	48%	10
Berardi et al[36]	CDDP + GEM	35 mg/m2, weekly	≥ 70	48	31.8%	9
Feliu et al[37]	CDDP + GEM	50 mg/m2	≥ 70	46	35%	10.2
Moscetti et al[38]	CDDP + GEM	75 mg/m², day 2	≥ 65	46	45.6%	15
Ohe et al[42]	CDDP + TXT	25 mg/m2, weekly	≥ 75	33	52%	15.8

¹Including 3 unfit patients; CDDP: Cisplatin; VNR: Vinorelbine; GEM: Gemcitabine; TXT: Docetaxel; RR: Response rate; MST: Median survival time; S: Survival.